Sector Alpha Week of 2026-09-11
Not SEBI Registered !! Not Investment advice !!
Sector Alpha — machine-written from the numbers · Data as of 2026-09-11

Yogi Ltd

YOGI
Trading

Yogi Ltd's three tracks disagree. Price, valuation and the earnings engine each tell a different story — the next quarter or two settles it.

The sharpest disagreement: annual EPS moved +1,255.6% against a −9.1% price move — the market has not yet caught up with the delivery.

The price is in a confirmed uptrend (172 weeks in) while the P/E sits at the 68th percentile of its own 1-year range. Underneath, the last four quarters read deteriorating — profit −125.6% year on year, and −1,200% of the last 2 years' profit arrived as cash. What settles it: whether the price catches up with earnings that have already moved.

Price
₹161
−9.1% 1Y
P/E
54.1×
68th pctile
of its own 1-year range
Revenue (Jun 26)
₹48.6 Cr
−46.2% YoY
Profit (Jun 26)
₹−1.6 Cr
−125.6% YoY
ROE
17%
FY26
Cash conversion
−1,200%
of profit, last 2 FY
Unverified figures: Some figures on this page come from a second financial-data feed that could not be cross-checked against the primary source — the two do not share enough overlapping reported history to compare. They are drawn, because they are the only evidence there is, and every section carrying one is marked unverified.
01 · Price story

Price story Before the numbers, the tape. A stock price moves through four repeating seasons: a flat base (stage 1), an advance (2), a top (3), a decline (4). Where the price sits in that cycle frames everything below.

Yogi Ltd trades at ₹161, in a confirmed uptrend and 172 weeks into that stage. That is −1.2% against its own 200-day average. It sits at 22% of a 52-week range of ₹152 to ₹194. On relative strength it is currently behind the NIFTY 500 on a trailing-13-week view (2 weeks and counting).

Today the stock is in a confirmed uptrend — week 172 of stage 2. At ₹161 it trades −1.2% versus its 200-day average and sits at 22% of its 52-week range (₹152–₹194).

Sep 26: ₹161 Weekly closing price (₹) with 50- and 200-day averages; shaded bands mark the price stage (grey base, green advance, amber top, red decline). 3-year window.
−1.2% versus the 200-day line, week 172 of stage 2
Price50-day avg200-day avg
S2₹207₹159₹110₹60.8₹11.9₹161₹163Sep 23May 24Jan 25Sep 25Sep 26
S2₹207₹159₹110₹60.8₹11.9₹161₹163Sep 23Jan 25Sep 26
Beating or trailing, week by week since 2016 Each cell is one week from 2016 to now (439 weeks): the stock's trailing 13-week return minus the NIFTY 500's, green ahead / red behind (±25% ramp). Grey cells are the 13-week warm-up or weeks where the NIFTY 500 reading is not held.
trailing 13-week return vs the NIFTY 500
Mar 16Sep 26

Against the market, two honest reads. Cumulative: over the last 10.5 years the stock moved +1,894% while the NIFTY 500 moved +267% — ahead of the index over the full window. Recent form: on a trailing-13-week view the stock is currently behind (2 weeks and counting; last ahead the week of 2026-08-28) — the ribbon below is that same metric, week by week.

What would end the trend, mechanically: two Friday closes in a row below the 200-day line. That is the exit rule — no debates.

02 · Valuation

Valuation P/E is the price of ₹1 of annual profit: how many rupees the market pays for each rupee the company earns in a year.

Yogi Ltd trades at 54.1× P/E, mid-range by its own standards (68th percentile). Its long-run median P/E is 40.2×, measured across 1.3 years of weekly readings. This places the multiple against the stock’s own record, and says nothing about what the business is worth.

Today's P/E of 54.1× is mid-range by its own standards (68th percentile), against a long-run median of 40.2× measured over 1.3 years of weekly readings. This is a comparison against the stock's own history — not a claim about what it is worth.

P/E 54.1× vs a 40.2× long-run median P/E, weekly (left axis); earnings per share, trailing twelve months, weekly (right axis). 1.3-year window; loss-period spikes above 121× shown pinned at the top. The eps (ttm) bars are red where the reading is lower than the quarter before.
mid-range by its own standards (68th percentile)
P/EMedianEPS (TTM) (quarterly)
127.6×₹5.3102.2×₹4.076.8×₹2.651.5×₹1.326.1×₹0.0×52.90×₹3May 25Sep 25Jan 26May 26Sep 26
127.6×₹5.3102.2×₹4.076.8×₹2.651.5×₹1.326.1×₹0.0×52.90×₹3May 25Jan 26Sep 26
P/E
54.1×
68th percentile of 1y

Why the multiple sits where it does: over the past year annual EPS moved +1,255.6% against a −9.1% price move — earnings outran the price, pushing the multiple DOWN its own range.

Put together: the multiple is full against its own past, so the story rests on the earnings line underneath it, not the multiple.

03 · Stage: No read

Stage: No read Every business sits somewhere on a fundamental arc, and this page names the spot before anything else. The last twelve quarters of revenue, profit and EPS growth — plus the return the business earns on its capital — are read as curves: Deteriorating (the curves are falling), Turning around (a trough has just formed and the last few quarters lift off it), Improving (the climb off the trough is sustained), Consistent (steadily positive with healthy returns), Topping out (still high but decelerating from the peak). When the curves genuinely disagree the read is Mixed; too little history is No read. CAGR (compound annual growth rate) is the smooth yearly pace that turns the starting value into the latest one — the fairest way to compare growth across different time spans. Read the columns together: if the 1-year number towers over the 10-year, recent growth is running hotter than the long-run trend. A dash means that window is not held, or the base year was a loss (where a growth rate is not meaningful).

Yogi Ltd reads as no read on its fundamental arc. Under eight usable quarters on the growth trio — not enough history for an honest trajectory read.

Growth, year by year: revenue +295.5% in FY26, profit +2,000.0% Year-over-year growth per fiscal year, %: revenue (left axis); net profit and EPS (right axis — profit growth swings far wider). Zero line drawn. Turnaround-year spikes shown pinned (▲).
Revenue YoYProfit YoYEPS YoY
296.7%301.2%296.1%300.6%295.5%300.0%294.9%299.4%294.3%298.8%%%295.5%300%FY24FY25FY26
296.7%301.2%296.1%300.6%295.5%300.0%294.9%299.4%294.3%298.8%%%295.5%300%FY24FY25FY26
Three growth curves, twelve quarters Year-on-year growth of trailing-twelve-month revenue (left axis), profit and EPS (right axis — they swing far wider), % at each quarter-end. Where the trailing-twelve-month history is short, the curve falls back to single-quarter year-on-year growth — noisier, and the classifier smooths and caps base-effect spikes before reading. Base-effect spikes shown pinned (▲). A missing point means that reading is not held for the quarter.
the trajectory the stage is read from
RevenueProfitEPS
312%334%254%211%197%87%139%−36%82%−160%%%97.5%−125.6%69.8%Mar 24Jun 25Jun 26
312%334%254%211%197%87%139%−36%82%−160%%%97.5%−125.6%69.8%Mar 24Jun 25Jun 26
ROE Annual readings — the quarterly balance-sheet pieces this curve needs are not held for this stock, so the returns read moves once a year and carries less weight in the call.
the return curve, annual readings
ROE
18%13%8.0%2.8%−2.4%%17%FY24FY25FY26
18%13%8.0%2.8%−2.4%%17%FY24FY25FY26
ROE
Rising
latest 17.0% · span −1.0%–17.0%

Why it matters: with too little history, an honest page says so instead of guessing a trajectory.

One or more growth curves carry a base-effect spike — a large year-on-year move off a near-zero or loss-making comparable quarter. Those spikes are capped before the classifier reads the trajectory, and shown pinned on the chart, so a single distorted quarter does not drive the stage call.

Return readings here are annual, not quarterly — read as level and direction only; they can confirm the growth curves but never drive the stage on their own.

Fewer than eight usable quarters on the growth curves — this page will not guess a trajectory from a stub of history.

Compound annual growth rate (%) Compound annual growth rate over each window, %. Revenue, profit and EPS from fiscal-year figures; share price is the price CAGR over the same spans. A dash = that window is not held, or the base was a loss.
1yr3yr5yr10yr
Revenue+295.5%
Profit+2,000.0%
EPS+1,255.6%
Share price−9.1%+78.9%+85.1%+34.9%
Revenue YoY (Jun 26)
−46.2%
latest quarter vs a year ago
Profit YoY (Jun 26)
−125.6%
latest quarter vs a year ago
04 · 4-Factor Sector Score

4-Factor Sector Score

47.9/100 — rank 21 of 52 in Trading · 58% evidence confidence

Yogi Ltd scores 47.9 out of 100 against the 52 companies it is compared with in Trading, ranking 21. Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral.

The four contributions add to the total exactly: 20.3 + 9.9 + 9.5 + 8.2 = 47.9. This is the SAME number shown on the sector comparison — it is computed once, for the whole peer set, and read here.

What would change it: The read weakens if profit growth turns negative or margin improvement reverses while sector-relative strength deteriorates.

05 · Revenue

Revenue Revenue is the top line: everything the company billed its customers in the period.

Yogi Ltd reported ₹48.6 Cr of revenue in the Jun 26 quarter, −46.2% year on year. The last full year, FY26, came in at ₹439 Cr. The last four reported quarters add to ₹398 Cr. A multi-year compound rate is not shown because the annual history behind it is too short to compute one honestly.

FY26 revenue came in at ₹439 Cr (+295.5% on the year). The latest quarter (Jun 26) printed ₹48.6 Cr, −46.2% year on year.

FY26 revenue ₹439 Cr (+295.5% YoY) Revenue bars, ₹ Cr (left); YoY growth-% line (right). 3-year window. A bar is red when it is lower than the year before.
RevenueYoY growth
474296.7%356296.1%237295.5%119294.9%0294.3%₹ Cr%₹439295.5%FY24FY25FY26
474296.7%356296.1%237295.5%119294.9%0294.3%₹ Cr%₹439295.5%FY24FY25FY26
Jun 26: ₹48.6 Cr (−46.2% YoY) Quarterly revenue bars, ₹ Cr (left); YoY growth-% line (right). Last 12 quarters. A bar is red when it is lower than the quarter before.
Revenue (quarterly)YoY growth
17049%12723%85−2.3%42−28%0−53%₹ Cr%₹49−46.2%Mar 24Jun 25Jun 26
17049%12723%85−2.3%42−28%0−53%₹ Cr%₹49−46.2%Mar 24Jun 25Jun 26
06 · Operating margin

Operating margin Operating margin is what is left of every ₹100 of sales after running the business, before interest and tax. It is the cleanest read on pricing power and cost control.

A clean operating margin is not in our numbers for Yogi Ltd — its accounts do not report the operating-profit line this section reads, which is common for lenders and holding companies. The sections above and below carry the readings this company's filings do support.

This company's accounts do not report the operating-profit line this section reads — common for lenders and holding companies classified outside the financial bucket. The revenue and net-profit sections are the cleaner reads for Yogi Ltd.

🚨 Why the margin moved: operating margin went −5.9 pp year on year while gross margin went −5.7 pp — the loss came mostly from the gross line: input costs and pricing.

07 · Net profit

Net profit Net profit is what survives every cost, interest and tax — the number EPS, dividends and book value all grow from.

Yogi Ltd posted a net loss of ₹1.6 Cr in the Jun 26 quarter. Full-year FY26 profit was ₹21.0 Cr. That loss is 3.3% of the quarter's revenue. The same quarter a year earlier earned ₹6.3 Cr. 3 of the last 9 reported quarters were loss-making.

Jun 26 profit was ₹−1.6 Cr, −125.6% year on year. On the full year, FY26 printed ₹21.0 Cr (+2,000.0%).

FY26 profit ₹21.0 Cr (+2,000.0% YoY) Net profit bars, ₹ Cr (left); YoY growth-% line (right). 3-year window. A bar is red when it is lower than the year before.
Net profitYoY growth
232,001.2%172,000.6%112,000.0%61,999.4%01,998.8%₹ Cr%₹212,000%FY24FY25FY26
232,001.2%172,000.6%112,000.0%61,999.4%01,998.8%₹ Cr%₹212,000%FY24FY25FY26
Jun 26: ₹−1.6 Cr (−125.6% YoY) Quarterly net profit bars, ₹ Cr (left); YoY growth-% line (right). Last 12 quarters. A bar is red when it is lower than the quarter before.
Net profit (quarterly)YoY growth
101,352%7956%4559%1162%−2−235%₹ Cr%₹−2−125.6%Mar 24Jun 25Jun 26
101,352%7956%4559%1162%−2−235%₹ Cr%₹−2−125.6%Mar 24Jun 25Jun 26
08 · Cash flow — the router

Cash flow — the router The P&L says what was earned; the cash-flow statement says what actually arrived. Operating cash flow (CFO) against profit is the cleanest lie detector in the accounts.

Over the last 2 fiscal years −1,200% of Yogi Ltd's reported profit arrived as operating cash — a gap worth watching. In FY26 that was ₹−192 Cr of operating cash against ₹21.0 Cr of profit. After ₹9.0 Cr of capital spending, ₹−201 Cr was left as free cash. Cash resolution here is annual, because quarterly cash statements are not published.

FY26: operating cash of ₹−192 Cr against reported profit of ₹21.0 Cr, leaving free cash of ₹−201 Cr after ₹9.0 Cr of capital spending. Across the last 2 fiscal years the conversion rate is −1,200% of profit.

Cash-flow readings here are annual — that is the resolution our series carries, so this section moves once a year.

FY26: CFO ₹−192 Cr vs profit ₹21.0 Cr Operating cash flow and net profit by fiscal year, ₹ Cr; the line is free cash flow (CFO minus capital spending). 3-year window, annual resolution.
−1,200% of 2-year profit arrived as cash
Operating cashNet profitFree cash
39−26−90−154−219₹ Cr₹−192₹21₹−201FY24FY25FY26
39−26−90−154−219₹ Cr₹−192₹21₹−201FY24FY25FY26
FY26: CFO = −914% of profit (three-year rate −1,200%) Operating cash as a share of net profit, per fiscal year, % (line). Dashed line = 100% — every unit of profit arriving as cash.
Conversion100%
684%−1,433%−3,550%−5,667%−7,784%%−914%FY24FY25FY26
684%−1,433%−3,550%−5,667%−7,784%%−914%FY24FY25FY26

🚨 Why: conversion is measured cleanly, but the working-capital day-counts behind it sit below what we hold — the move is shown without inventing its driver.

Router verdict: the visible cash user is investment — the next section checks what the spending is buying.

09 · Where the cash goes

Where the cash goes Working capital is the cash tied up between paying suppliers and getting paid: debtor days (customers owe), inventory days (stock waits), and the cash conversion cycle (the whole loop, in days of sales).

Yogi Ltd does not report the debtor, inventory and payable day-counts a cash cycle is built from, so this section reads the investment side instead. Capital spending ran ₹9.0 Cr over the last 2 years. Averaged over those years that is 1.0% of FY26 revenue a year.

Working-capital day-counts are not in our numbers for this stock, so this section reads the investment side — where the cash is being put to work.

On the investment side: capital spending of ₹9.0 Cr over the last 2 fiscal years. Capital work-in-progress stands at ₹0.0 Cr (FY26) — capacity paid for but not yet earning.

FY26: capex ₹9.0 Cr, work-in-progress ₹0.0 Cr Capital spending per fiscal year, ₹ Cr (bars); capital work-in-progress, ₹ Cr (line). Quarterly capital-spending history is not held for India — annual is the honest resolution.
steady investment
CapexWork-in-progress
107520₹ Cr₹9₹0FY25FY26
107520₹ Cr₹9₹0FY25FY26

The synthesis: the cash is going into capacity, not disappearing into the cycle — the question becomes whether the new capacity earns.

10 · Return on equity

Return on equity Return on equity (ROE) is the profit the business earns on its shareholders’ money. With the full capital-employed split not in our numbers, ROE is the cleanest long ladder we can draw here.

Yogi Ltd earns a ROE of 17% in FY26. That is up from a trough of −1% in FY24. A return-on-invested-capital spread against the cost of capital is not computable from what is held here. The wiring behind it is 4.8% net margin on 0.62× asset turns.

FY26 ROE is 17%, recovered from a FY24 trough of −1% — the full ladder below shows the fall and the climb, undoctored.

Why the return is what it is — the wiring (FY26): 4.8% net margin × 0.62× asset turns × 5.12× balance-sheet leverage ≈ 15.2% on equity. Margin does its share; leverage is a meaningful part of the equation.

FY26: ROE 17% Return on equity by fiscal year, % (line). 3-year window, dips included. Dashed line = the 12.0% cost of capital used on this page.
the climb back from FY24's −1%
ROEWACC
18%13%8.0%2.8%−2.4%%17%FY24FY25FY26
18%13%8.0%2.8%−2.4%%17%FY24FY25FY26
11 · Debt

Debt Debt-to-equity says how much of the business is funded by borrowings; interest cover says how many times operating profit pays the interest bill. Low and high, respectively, is the safe corner.

Yogi Ltd carries ₹253 Cr of borrowings against ₹139 Cr of equity in FY26, a debt-to-equity of 1.82. Over 2 years borrowings went from ₹18.0 Cr to ₹253 Cr. Capital spending ran ₹9.0 Cr across the last 2 of those years.

FY26: borrowings of ₹253 Cr against equity of ₹139 Cr — a debt-to-equity of 1.82. Over 2 years borrowings went from ₹18.0 Cr to ₹253 Cr while capital spending ran ₹9.0 Cr in just the last 2 — part of the build-out is riding on borrowed money.

FY26: borrowings ₹253 Cr at 1.82× equity Borrowings by fiscal year, ₹ Cr (bars); debt-to-equity, × (line). 3-year window. Quarterly balance-sheet history is not held for India — annual is the honest resolution.
the debt trajectory
BorrowingsDebt-to-equity
2731.9×2051.5×1371.0×680.5×00.1×₹ Cr×₹2531.82×FY24FY25FY26
2731.9×2051.5×1371.0×680.5×00.1×₹ Cr×₹2531.82×FY24FY25FY26
12 · Ownership

Ownership Who owns the stock, quarter by quarter: promoters (the controlling owners), foreign and domestic institutions, and the public. Steady accumulation by people close to the numbers is a signal; a quiet register is also an answer.

Promoters added 8.3 points of Yogi Ltd over 8 quarters, the biggest move on the register. That takes promoters to 62.7% of the company. The register is read on the four disclosed classes only; nothing is inferred between filings.

The register over the last two years — Promoters: +8.3 points over 8 quarters to 62.7%.

Why the register moved: promoters drove it (+8.3 points) — steady accumulation by institutions reading the same numbers this page reads.

Fiscal-year ends: promoters +6.7 pts from Mar 24 to Mar 26 Shareholding at each fiscal-year end (March quarter), % of the company. 3 year-ends held.
PromotersPublic
63%56%50%44%37%%61.1%38.9%Mar 24Mar 25Mar 26
63%56%50%44%37%%61.1%38.9%Mar 24Mar 25Mar 26
Promoters added 8.3 points over 8 quarters Shareholding by holder class, % of the company, quarterly, last 13 quarters.
PromotersPublic
65%57%50%43%35%%62.7%37.3%Jun 23Dec 24Jun 26
65%57%50%43%35%%62.7%37.3%Jun 23Dec 24Jun 26
13 · Safety line

Safety line The Z-score estimates how far a company sits from balance-sheet distress — above roughly 3 is safe, below roughly 1.8 is the danger zone. It was built for manufacturers, so it is not applied to banks and lenders.

Yogi Ltd: the Z-score is not available for this stock, so we say so rather than invent one. It is a distance-to-distress estimate from the balance sheet, not a forecast of failure. The debt, cash-flow and return sections above carry the balance-sheet evidence this page does hold, and each of them states its own reporting date.

The safety line in one sentence: the Z-score is not available for this stock, so we say so rather than invent one.

14 · Related companies · Trading
CompanyScorePrice stageGrowth & earnings/35Capital efficiency/25Valuation/20Relative strength/20
1Onix Solar Energy LtdONIXSOLAR 70.9/100Favorable setup69% evidence 28.9/35 Revenue 26.2% · PAT 100% · OPM change 23 pp 95% evidence 18.3/25 ROCE 32% · OPM 30% 76% evidence 10.3/20 P/E 24.4× · PEG — 15% evidence 13.4/20 RS sector 68.4% · RS bench -3.5% · 1Y 49.1%12 of 12 weeks ahead 70% evidence
Exact sum: 28.9 + 18.3 + 10.3 + 13.4 = 70.9 · Decision use: Confirmed research leader: earnings, capital efficiency and relative strength agree. Move to management, catalyst and risk diligence.
2Rashi Peripherals LtdRPTECH 69.0/100Favorable setup75% evidence LEADER 24.9/35 Revenue 40.4% · PAT 50.2% · OPM change -0.3 pp 95% evidence 14.7/25 ROCE 17% · OPM 3% 76% evidence 10.7/20 P/E 17.1× · PEG — 15% evidence 18.7/20 RS sector 51.6% · RS bench 69.1% · 1Y 176.9%12 of 12 weeks ahead 100% evidence
Exact sum: 24.9 + 14.7 + 10.7 + 18.7 = 69 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.
3Nupur Recyclers LtdNRL 67.9/100Favorable setup87% evidence LEADER 22.5/35 Revenue 40.6% · PAT 29.8% · OPM change 3.6 pp 95% evidence 16.5/25 ROCE 15.1% · OPM 11.6% 95% evidence 9.2/20 P/E 53.6× · PEG — 50% evidence 19.7/20 RS sector 66.4% · RS bench 88.4% · 1Y 89.6%12 of 12 weeks ahead 100% evidence
Exact sum: 22.5 + 16.5 + 9.2 + 19.7 = 67.9 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.
4Magnus Steel & Infra Ltd517320 67.5/100Thin evidence · provisional56% evidence 27.8/35 Revenue 100% · PAT 100% · OPM change 1.6 pp 83% evidence 18.5/25 ROCE 171% · OPM 21.3% 76% evidence 9.2/20 P/E 92.5× · PEG — 15% evidence 12.0/20 RS sector — · RS bench 46.1% · 1Y 1449.6%0 of 1 week ahead to 2026-06-28 25% evidence
Exact sum: 27.8 + 18.5 + 9.2 + 12 = 67.5 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral.
5Vision Infra Equipment Solutions LtdVIESL 67.3/100Thin evidence · provisional56% evidence TURNING 19.0/35 Revenue — · PAT — · OPM change 0 pp 26% evidence 19.8/25 ROCE 22.6% · OPM 26% 95% evidence 10.9/20 P/E 14.9× · PEG — 15% evidence 17.6/20 RS sector 26.9% · RS bench 44.5% · 1Y 122.8%9 of 12 weeks ahead 100% evidence
Exact sum: 19 + 19.8 + 10.9 + 17.6 = 67.3 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral.
6Shankara Buildpro LtdBUILDPRO 63.3/100Mixed-positive evidence63% evidence BREAKING OUT 25.6/35 Revenue 26.3% · PAT 41.9% · OPM change -0.2 pp 100% evidence 17.3/25 ROCE 39% · OPM 3.2% 100% evidence 10.4/20 P/E 22.8× · PEG — 15% evidence 10.0/20 RS sector — · RS bench — · 1Y —8 of 12 weeks ahead 0% evidence
Exact sum: 25.6 + 17.3 + 10.4 + 10 = 63.3 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.
7Ivalue Infosolutions LtdIVALUE 60.4/100Mixed-positive evidence60% evidence ASLEEP 20.6/35 Revenue 5.4% · PAT 22.1% · OPM change 5.6 pp 95% evidence 18.6/25 ROCE 25.4% · OPM 10% 95% evidence 11.2/20 P/E 11.4× · PEG — 15% evidence 10.0/20 RS sector — · RS bench — · 1Y -19.4%6 of 10 weeks ahead 0% evidence
Exact sum: 20.6 + 18.6 + 11.2 + 10 = 60.4 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.
8Sudarshan Pharma Industries Ltd543828 60.3/100Mixed-positive evidence82% evidence LEADER 20.9/35 Revenue 32.9% · PAT 24.3% · OPM change 1.5 pp 95% evidence 13.6/25 ROCE 15.1% · OPM 9.1% 76% evidence 8.9/20 P/E 39.2× · PEG — 50% evidence 16.9/20 RS sector 17.5% · RS bench 33.4% · 1Y 25.2%12 of 12 weeks ahead 100% evidence
Exact sum: 20.9 + 13.6 + 8.9 + 16.9 = 60.3 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.
9Euro Pratik Sales LtdEUROPRATIK 59.9/100Mixed-positive evidence73% evidence ASLEEP 15.1/35 Revenue 23.9% · PAT 29% · OPM change -8 pp 100% evidence 19.5/25 ROCE 38.4% · OPM 26% 100% evidence 15.3/20 P/E 29.1× · PEG 0.62 65% evidence 10.0/20 RS sector — · RS bench — · 1Y 4.7%6 of 10 weeks ahead 0% evidence
Exact sum: 15.1 + 19.5 + 15.3 + 10 = 59.9 · Decision use: Cheap but unconfirmed: require improving earnings before treating the valuation as an opportunity.
10Tembo Global Industries LtdTEMBO 59.0/100Mixed-positive evidence80% evidence TURNING 22.2/35 Revenue 34% · PAT 55.7% · OPM change 5 pp 95% evidence 18.4/25 ROCE 22.8% · OPM 16% 95% evidence 11.3/20 P/E 10.2× · PEG — 15% evidence 7.1/20 RS sector -17.4% · RS bench -4.5% · 1Y -10.2%2 of 12 weeks ahead 100% evidence
Exact sum: 22.2 + 18.4 + 11.3 + 7.1 = 59 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.
11Mangalam Global Enterprise LtdMGEL 58.7/100Mixed-positive evidence80% evidence 25.7/35 Revenue 41.4% · PAT 100% · OPM change 0.5 pp 95% evidence 15.8/25 ROCE 17% · OPM 1.9% 95% evidence 11.1/20 P/E 13× · PEG — 15% evidence 6.1/20 RS sector -14.5% · RS bench -0.2% · 1Y -3.5%6 of 7 weeks ahead to 2026-08-09 100% evidence
Exact sum: 25.7 + 15.8 + 11.1 + 6.1 = 58.7 · Decision use: Acceleration candidate, not a confirmed leader: earnings are strong but sector-relative strength is -14.5% and the one-year return is -3.5%. Do not upgrade until sector-relative strength is above zero and another reported period confirms growth.
12Arisinfra Solutions LtdARIS 57.6/100Mixed-positive evidence65% evidence TURNING 22.0/35 Revenue 45.3% · PAT 100% · OPM change 2 pp 95% evidence 15.1/25 ROCE 15.6% · OPM 11% 95% evidence 10.8/20 P/E 15.5× · PEG — 15% evidence 9.7/20 RS sector — · RS bench -1.2% · 1Y -12.3%4 of 10 weeks ahead 25% evidence
Exact sum: 22 + 15.1 + 10.8 + 9.7 = 57.6 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.
13Aayush Art and Bullion Ltd540718 56.4/100Thin evidence · provisional54% evidence BREAKING OUT 21.2/35 Revenue 100% · PAT — · OPM change 1.6 pp 35% evidence 13.2/25 ROCE 18.9% · OPM 6% 76% evidence 8.9/20 P/E 245× · PEG — 15% evidence 13.1/20 RS sector -1.1% · RS bench 13.5% · 1Y 29.2%3 of 12 weeks ahead 100% evidence
Exact sum: 21.2 + 13.2 + 8.9 + 13.1 = 56.4 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral.
14Patel Retail LtdPATELRMART 53.8/100Mixed-positive evidence65% evidence ASLEEP 18.1/35 Revenue 42.3% · PAT 59.7% · OPM change -2.2 pp 95% evidence 14.3/25 ROCE 15.3% · OPM 6.1% 95% evidence 10.8/20 P/E 16.9× · PEG — 15% evidence 10.6/20 RS sector — · RS bench 2.8% · 1Y -18.4%5 of 10 weeks ahead 25% evidence
Exact sum: 18.1 + 14.3 + 10.8 + 10.6 = 53.8 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.
15Prostarm Info Systems LtdPROSTARM 52.0/100Mixed-positive evidence65% evidence BASING 17.1/35 Revenue 30.5% · PAT 19.1% · OPM change 1.4 pp 95% evidence 16.1/25 ROCE 18% · OPM 8.5% 95% evidence 10.5/20 P/E 22× · PEG — 15% evidence 8.3/20 RS sector — · RS bench -12.2% · 1Y -35.5%0 of 10 weeks ahead 25% evidence
Exact sum: 17.1 + 16.1 + 10.5 + 8.3 = 52 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.
16Fabtech Technologies LtdFABTECH 50.8/100Thin evidence · provisional52% evidence TURNING 17.5/35 Revenue 14.2% · PAT 41% · OPM change 14.8 pp 71% evidence 12.3/25 ROCE 13.6% · OPM 5.7% 95% evidence 11.0/20 P/E 13.4× · PEG — 15% evidence 10.0/20 RS sector — · RS bench — · 1Y —0 of 10 weeks ahead 0% evidence
Exact sum: 17.5 + 12.3 + 11 + 10 = 50.8 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral.
17Lloyds Enterprises LtdLLOYDSENT 50.3/100Mixed-positive evidence75% evidence TURNING 18.1/35 Revenue 33% · PAT -21.4% · OPM change 9 pp 95% evidence 11.3/25 ROCE 3.7% · OPM 16% 76% evidence 9.1/20 P/E 93.3× · PEG — 15% evidence 11.8/20 RS sector -5% · RS bench 8.7% · 1Y -6%10 of 12 weeks ahead 100% evidence
Exact sum: 18.1 + 11.3 + 9.1 + 11.8 = 50.3 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.
18BMW Ventures LtdBMW 50.0/100Thin evidence · provisional55% evidence 16.9/35 Revenue 18.5% · PAT 24.2% · OPM change -0.6 pp 95% evidence 11.9/25 ROCE 12% · OPM 3.4% 76% evidence 11.2/20 P/E 12.2× · PEG — 15% evidence 10.0/20 RS sector — · RS bench — · 1Y -18.7%0 of 10 weeks ahead 0% evidence
Exact sum: 16.9 + 11.9 + 11.2 + 10 = 50 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral.
19SG Mart LtdSGMART 48.9/100Mixed-negative evidence93% evidence LEADER 13.9/35 Revenue 10.4% · PAT 14.7% · OPM change 1.4 pp 100% evidence 8.6/25 ROCE 10.2% · OPM 4.5% 100% evidence 8.2/20 P/E 76.1× · PEG 1.92 65% evidence 18.2/20 RS sector 34.9% · RS bench 51.7% · 1Y 106.8%12 of 12 weeks ahead 100% evidence
Exact sum: 13.9 + 8.6 + 8.2 + 18.2 = 48.9 · Decision use: Price leads the evidence: RS versus the benchmark is 51.7%, but earnings trajectory is weak. Wait for revenue and profit confirmation.
20Bizotic Commercial Ltd543926 48.7/100Thin evidence · provisional58% evidence BASING 19.8/35 Revenue — · PAT — · OPM change 0 pp 26% evidence 18.6/25 ROCE 26.8% · OPM 8% 76% evidence 9.7/20 P/E 34.1× · PEG — 50% evidence 0.6/20 RS sector -86.7% · RS bench -18.3% · 1Y -72.4%0 of 12 weeks ahead 100% evidence
Exact sum: 19.8 + 18.6 + 9.7 + 0.6 = 48.7 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral.
21Yogi Ltdthis pageYOGI 47.9/100Thin evidence · provisional58% evidence 20.3/35 Revenue 97.5% · PAT 68.1% · OPM change -5.9 pp 62% evidence 9.9/25 ROCE 12.8% · OPM 2.6% 76% evidence 9.5/20 P/E 54.1× · PEG — 15% evidence 8.2/20 RS sector -6.5% · RS bench -2.1% · 1Y -11.1%2 of 12 weeks ahead 70% evidence
Exact sum: 20.3 + 9.9 + 9.5 + 8.2 = 47.9 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral.
22Shiv Aum Steels LtdSHIVAUM 47.4/100Thin evidence · provisional55% evidence BREAKING OUT 16.9/35 Revenue — · PAT — · OPM change 1.3 pp 45% evidence 11.4/25 ROCE 8% · OPM 4.7% 95% evidence 7.2/20 P/E 66.8× · PEG — 50% evidence 11.9/20 RS sector — · RS bench 38.3% · 1Y —6 of 6 weeks ahead 25% evidence
Exact sum: 16.9 + 11.4 + 7.2 + 11.9 = 47.4 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral.
23Dhunseri Ventures LtdDVL 46.8/100Mixed-negative evidence87% evidence BREAKING OUT 12.6/35 Revenue -20% · PAT 31.7% · OPM change -12 pp 95% evidence 9.7/25 ROCE 6.7% · OPM 39% 95% evidence 11.9/20 P/E 5.3× · PEG — 50% evidence 12.6/20 RS sector -7.1% · RS bench 8% · 1Y -14.9%7 of 12 weeks ahead 100% evidence
Exact sum: 12.6 + 9.7 + 11.9 + 12.6 = 46.8 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.
24Adani Enterprises LtdADANIENT 45.5/100Mixed-negative evidence93% evidence TURNING 14.3/35 Revenue 18.1% · PAT 4.2% · OPM change 0 pp 100% evidence 8.5/25 ROCE 5.8% · OPM 15% 100% evidence 7.7/20 P/E 174× · PEG 1.96 65% evidence 15.0/20 RS sector 8.6% · RS bench 23.9% · 1Y 38.4%10 of 12 weeks ahead 100% evidence
Exact sum: 14.3 + 8.5 + 7.7 + 15 = 45.5 · Decision use: Price leads the evidence: RS versus the benchmark is 23.9%, but earnings trajectory is weak. Wait for revenue and profit confirmation.
25MMTC LtdMMTC 44.8/100Mixed-negative evidence96% evidence ASLEEP 15.1/35 Revenue 0% · PAT 100% · OPM change -1270 pp 100% evidence 8.0/25 ROCE 8.7% · OPM — 84% evidence 15.3/20 P/E 46.1× · PEG 0.92 100% evidence 6.4/20 RS sector -14.9% · RS bench -1.9% · 1Y -4.1%3 of 12 weeks ahead 100% evidence
Exact sum: 15.1 + 8 + 15.3 + 6.4 = 44.8 · Decision use: Cheap but unconfirmed: require improving earnings before treating the valuation as an opportunity.
26State Trading Corporation of India LtdSTCINDIA 42.5/100Mixed-negative evidence67% evidence ASLEEP 19.6/35 Revenue — · PAT 100% · OPM change -14.6 pp 67% evidence 5.6/25 ROCE -0.9% · OPM — 80% evidence 11.9/20 P/E 14× · PEG — 50% evidence 5.4/20 RS sector -28.7% · RS bench -5.6% · 1Y -5.6%2 of 11 weeks ahead 70% evidence
Exact sum: 19.6 + 5.6 + 11.9 + 5.4 = 42.5 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.
27RRP Semiconductor LtdRRP 41.1/100Thin evidence · provisional54% evidence 11.4/35 Revenue -80% · PAT -80% · OPM change 3.3 pp 71% evidence 5.4/25 ROCE -32.7% · OPM — 61% evidence 10.0/20 P/E — · PEG — 0% evidence 14.3/20 RS sector 65.3% · RS bench 0.8% · 1Y 66.5%0 of 1 week ahead 70% evidence
Exact sum: 11.4 + 5.4 + 10 + 14.3 = 41.1 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral.
28Cropster Agro Ltd523105 40.7/100Mixed-negative evidence65% evidence 16.0/35 Revenue 28.4% · PAT 6.5% · OPM change 2.1 pp 83% evidence 11.3/25 ROCE 12.4% · OPM 8.7% 76% evidence 10.1/20 P/E 31× · PEG — 15% evidence 3.3/20 RS sector -72.7% · RS bench -62.7% · 1Y -83.2%0 of 1 week ahead to 2026-08-09 70% evidence
Exact sum: 16 + 11.3 + 10.1 + 3.3 = 40.7 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.
29Hexa Tradex LtdHEXATRADEX 40.3/100Mixed-negative evidence65% evidence BASING 17.2/35 Revenue 0.4% · PAT 70.3% · OPM change 13.6 pp 71% evidence 6.1/25 ROCE -0.1% · OPM — 80% evidence 10.0/20 P/E — · PEG — 0% evidence 7.0/20 RS sector -16.8% · RS bench -3.7% · 1Y -12.7%0 of 12 weeks ahead 100% evidence
Exact sum: 17.2 + 6.1 + 10 + 7 = 40.3 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.
30Hardwyn India LtdHARDWYN 40.2/100Mixed-negative evidence87% evidence ASLEEP 13.8/35 Revenue 2.6% · PAT -8.5% · OPM change -0.2 pp 95% evidence 12.5/25 ROCE 4.8% · OPM 13% 95% evidence 12.1/20 P/E 50.6× · PEG — 50% evidence 1.8/20 RS sector -38.3% · RS bench -29.5% · 1Y -3.4%3 of 12 weeks ahead 100% evidence
Exact sum: 13.8 + 12.5 + 12.1 + 1.8 = 40.2 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.
31Blue Pearl Agriventures LtdBPAGRI 39.8/100Mixed-negative evidence69% evidence 20.5/35 Revenue 19.3% · PAT 59.1% · OPM change 0.3 pp 95% evidence 6.3/25 ROCE 2.2% · OPM 3.3% 76% evidence 8.7/20 P/E 514× · PEG — 15% evidence 4.3/20 RS sector -33.5% · RS bench -82.5% · 1Y -91.2%1 of 12 weeks ahead 70% evidence
Exact sum: 20.5 + 6.3 + 8.7 + 4.3 = 39.8 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.
32Pervasive Commodities Ltd517172 38.3/100Thin evidence · provisional52% evidence 12.7/35 Revenue 25.6% · PAT -8.3% · OPM change -6.1 pp 95% evidence 5.6/25 ROCE 0% · OPM -10.2% 76% evidence 10.0/20 P/E — · PEG — 0% evidence 10.0/20 RS sector — · RS bench — · 1Y — 0% evidence
Exact sum: 12.7 + 5.6 + 10 + 10 = 38.3 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral.
33Riddhi Siddhi Gluco Biols Ltd524480 38.0/100Mixed-negative evidence82% evidence FADING 12.4/35 Revenue -38% · PAT 38.4% · OPM change -2.8 pp 95% evidence 6.6/25 ROCE 2.7% · OPM -3% 76% evidence 6.5/20 P/E 37.3× · PEG — 50% evidence 12.5/20 RS sector 10.5% · RS bench 25.4% · 1Y 33.5%9 of 12 weeks ahead 100% evidence
Exact sum: 12.4 + 6.6 + 6.5 + 12.5 = 38 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.
34PTC India LtdPTC 36.6/100Mixed-negative evidence82% evidence BASING 11.2/35 Revenue 13.3% · PAT -43.1% · OPM change -3.9 pp 95% evidence 12.6/25 ROCE 13.4% · OPM 3.1% 76% evidence 9.7/20 P/E 8.8× · PEG — 50% evidence 3.1/20 RS sector -21.6% · RS bench -9.8% · 1Y -13%0 of 12 weeks ahead 100% evidence
Exact sum: 11.2 + 12.6 + 9.7 + 3.1 = 36.6 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.
35Neueon Corporation LtdNEUEON 35.6/100Thin evidence · provisional59% evidence ASLEEP 9.1/35 Revenue 17.8% · PAT -80% · OPM change -1039 pp 71% evidence 3.7/25 ROCE -40.4% · OPM — 80% evidence 10.0/20 P/E — · PEG — 0% evidence 12.8/20 RS sector 12.7% · RS bench -1.5% · 1Y —1 of 12 weeks ahead 70% evidence
Exact sum: 9.1 + 3.7 + 10 + 12.8 = 35.6 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral.
36Kothari Industrial Corporation LtdKOTIC 34.2/100Adverse evidence63% evidence BASING 18.8/35 Revenue 75.9% · PAT -80% · OPM change -41.8 pp 71% evidence 1.6/25 ROCE -28.9% · OPM -43% 95% evidence 10.0/20 P/E — · PEG — 0% evidence 3.8/20 RS sector -58.6% · RS bench -43.5% · 1Y -77.5%0 of 9 weeks ahead 70% evidence
Exact sum: 18.8 + 1.6 + 10 + 3.8 = 34.2 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.
37Shanti Overseas (India) LtdSHANTI 32.3/100Thin evidence · provisional56% evidence 11.2/35 Revenue -63.4% · PAT 100% · OPM change -200.5 pp 40% evidence 4.5/25 ROCE -25.2% · OPM -216.5% 71% evidence 13.1/20 P/E 3× · PEG — 50% evidence 3.5/20 RS sector -60.4% · RS bench -49.7% · 1Y -47.1%0 of 12 weeks ahead to 2026-03-29 70% evidence
Exact sum: 11.2 + 4.5 + 13.1 + 3.5 = 32.3 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral.
38BN Agrochem LtdBNAGROCHEM 32.2/100Adverse evidence77% evidence ASLEEP 12.9/35 Revenue 84.5% · PAT -61% · OPM change -9.4 pp 100% evidence 4.4/25 ROCE 4.4% · OPM 2.3% 100% evidence 9.0/20 P/E 117× · PEG — 15% evidence 5.9/20 RS sector -16.7% · RS bench -35.6% · 1Y -46.5%4 of 10 weeks ahead 70% evidence
Exact sum: 12.9 + 4.4 + 9 + 5.9 = 32.2 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.
39Uniphos Enterprises LtdUNIENTER 30.4/100Adverse evidence69% evidence BASING 12.6/35 Revenue -77.1% · PAT 100% · OPM change -0.9 pp 71% evidence 4.6/25 ROCE 0.8% · OPM — 80% evidence 8.8/20 P/E 31.4× · PEG — 50% evidence 4.4/20 RS sector -43.6% · RS bench -22% · 1Y -41%1 of 10 weeks ahead 70% evidence
Exact sum: 12.6 + 4.6 + 8.8 + 4.4 = 30.4 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.
40Oswal Agro Mills LtdOSWALAGRO 24.7/100Adverse evidence67% evidence 2.8/35 Revenue -80% · PAT -80% · OPM change -21782.3 pp 95% evidence 7.8/25 ROCE 2% · OPM — 80% evidence 10.0/20 P/E — · PEG — 0% evidence 4.1/20 RS sector -50.3% · RS bench -32% · 1Y -49.6%0 of 6 weeks ahead to 2026-08-16 70% evidence
Exact sum: 2.8 + 7.8 + 10 + 4.1 = 24.7 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.
41Mardia Samyoung Capillary Tubes Company LtdMSCTC 56.9/100Thin evidence · provisional32% evidence 20.8/35 Revenue 100% · PAT 100% · OPM change — 29% evidence 15.2/25 ROCE 22.6% · OPM 15.3% 57% evidence 8.6/20 P/E 687× · PEG — 15% evidence 12.3/20 RS sector — · RS bench 74.6% · 1Y 93.7%6 of 12 weeks ahead to 2026-03-08 25% evidence
Exact sum: 20.8 + 15.2 + 8.6 + 12.3 = 56.9 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral.
42Proventus Agrocom LtdPROV 56.7/100Thin evidence · provisional48% evidence BREAKING OUT 19.6/35 Revenue — · PAT — · OPM change 0.2 pp 26% evidence 12.4/25 ROCE 11.5% · OPM 1.8% 95% evidence 13.1/20 P/E 42.8× · PEG — 50% evidence 11.6/20 RS sector — · RS bench 26.9% · 1Y —12 of 12 weeks ahead 25% evidence
Exact sum: 19.6 + 12.4 + 13.1 + 11.6 = 56.7 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral.
43DC Infotech & Communication LtdDCI 56.3/100Thin evidence · provisional35% evidence 18.6/35 Revenue — · PAT — · OPM change 0.3 pp 24% evidence 17.6/25 ROCE 22.9% · OPM 4.7% 76% evidence 10.6/20 P/E 20.4× · PEG — 15% evidence 9.5/20 RS sector — · RS bench -1.6% · 1Y — 25% evidence
Exact sum: 18.6 + 17.6 + 10.6 + 9.5 = 56.3 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral.
44SK Minerals & Additives Ltd544584 55.8/100Thin evidence · provisional36% evidence TURNING 16.6/35 Revenue — · PAT — · OPM change 1.3 pp 39% evidence 19.0/25 ROCE 26.2% · OPM 10.7% 76% evidence 10.2/20 P/E 29.5× · PEG — 15% evidence 10.0/20 RS sector — · RS bench — · 1Y —3 of 4 weeks ahead 0% evidence
Exact sum: 16.6 + 19 + 10.2 + 10 = 55.8 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral.
45Monika Alcobev LtdMONIKA 54.0/100Thin evidence · provisional22% evidence 16.4/35 Revenue — · PAT — · OPM change -2 pp 15% evidence 17.0/25 ROCE 21% · OPM 15% 57% evidence 10.6/20 P/E 20.4× · PEG — 15% evidence 10.0/20 RS sector — · RS bench — · 1Y -10.9%0 of 12 weeks ahead to 2026-03-08 0% evidence
Exact sum: 16.4 + 17 + 10.6 + 10 = 54 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral.
46Shah Foods Ltd519031 53.6/100Thin evidence · provisional18% evidence TURNING 17.1/35 Revenue — · PAT — · OPM change -10.7 pp 7% evidence 15.3/25 ROCE — · OPM 18% 30% evidence 8.8/20 P/E 276× · PEG — 15% evidence 12.4/20 RS sector — · RS bench 103.9% · 1Y —4 of 4 weeks ahead 25% evidence
Exact sum: 17.1 + 15.3 + 8.8 + 12.4 = 53.6 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral.
47Pramara Promotions LtdPRAMARA 51.7/100Thin evidence · provisional47% evidence 16.6/35 Revenue — · PAT — · OPM change -1 pp 15% evidence 13.9/25 ROCE 15.2% · OPM 15% 71% evidence 6.9/20 P/E 51.3× · PEG — 50% evidence 14.3/20 RS sector 7.9% · RS bench 29% · 1Y 34.5%10 of 12 weeks ahead to 2026-04-19 70% evidence
Exact sum: 16.6 + 13.9 + 6.9 + 14.3 = 51.7 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral.
48Manbro Industries Ltd512595 50.9/100Thin evidence · provisional22% evidence 18.3/35 Revenue — · PAT — · OPM change 32.8 pp 5% evidence 13.1/25 ROCE — · OPM 6.6% 23% evidence 10.0/20 P/E — · PEG — 0% evidence 9.5/20 RS sector -17.3% · RS bench 37.2% · 1Y 62.6%12 of 12 weeks ahead to 2026-05-03 70% evidence
Exact sum: 18.3 + 13.1 + 10 + 9.5 = 50.9 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral.
49Le Merite Exports LtdLEMERITE 47.2/100Thin evidence · provisional40% evidence 18.9/35 Revenue — · PAT — · OPM change 0.9 pp 15% evidence 9.1/25 ROCE 8.6% · OPM 2.8% 71% evidence 9.3/20 P/E 87× · PEG — 15% evidence 9.9/20 RS sector -9% · RS bench 15% · 1Y 28.1%2 of 12 weeks ahead to 2026-05-17 70% evidence
Exact sum: 18.9 + 9.1 + 9.3 + 9.9 = 47.2 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral.
50Satani Bearings Ltd505703 45.2/100Thin evidence · provisional38% evidence TURNING 20.5/35 Revenue — · PAT 100% · OPM change — 33% evidence 4.7/25 ROCE 1% · OPM -3.7% 76% evidence 8.6/20 P/E 5197× · PEG — 15% evidence 11.4/20 RS sector — · RS bench 24.9% · 1Y 176.6%1 of 11 weeks ahead 25% evidence
Exact sum: 20.5 + 4.7 + 8.6 + 11.4 = 45.2 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral.
51Keto Motors Ltd537392 43.3/100Thin evidence · provisional38% evidence TURNING 16.3/35 Revenue — · PAT 100% · OPM change — 33% evidence 6.0/25 ROCE -0.3% · OPM 10.7% 76% evidence 8.5/20 P/E 7503× · PEG — 15% evidence 12.5/20 RS sector — · RS bench 272.8% · 1Y —4 of 4 weeks ahead 25% evidence
Exact sum: 16.3 + 6 + 8.5 + 12.5 = 43.3 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral.
52A-1 LtdA1L 41.0/100Thin evidence · provisional50% evidence 16.2/35 Revenue 8.3% · PAT -30.6% · OPM change -0.9 pp 53% evidence 10.7/25 ROCE 10.6% · OPM 2.9% 57% evidence 8.8/20 P/E 383× · PEG — 15% evidence 5.3/20 RS sector -24.5% · RS bench -16% · 1Y -8.6%6 of 12 weeks ahead to 2026-03-08 70% evidence
Exact sum: 16.2 + 10.7 + 8.8 + 5.3 = 41 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral.

Missing observations are not scored as bad. Their missing weight lowers confidence and pulls the final score toward neutral. PEG is not shown when the ratio cannot mean anything: the company must be making a profit, its price-to-earnings must be positive, and its three-year earnings growth must fall between 5% and 60%. Dividing a price multiple by a loss, or by growth measured off a tiny base, produces a number that looks precise and tells you nothing. Under relative strength, one mark per week shows the last 12 weeks: a mark is filled where the company led NIFTY 500 by 5% or more over the 13 weeks ending that week, which is the same test used everywhere on this site. Price stage places the company on the same six-step curve the sector itself is placed on — basing, turning, breaking out, leader, fading, asleep — read from how many weeks running it has led NIFTY 500 and whether that lead is widening or shrinking. It describes where the PRICE stands, not the earnings trajectory and not a recommendation, and it is left blank for a company whose weekly history is too short or too stale to read.

15 · Frequently asked questions

Frequently asked questions

What is Yogi Ltd's share price today?

Yogi Ltd trades at ₹161, −9.1% over the past year. The company is valued at ₹707 Cr. The stock sits at 22% of its 52-week range of ₹152–₹194, −1.2% versus its 200-day average. On the tape, the price is in a confirmed uptrend, 172 weeks in. — as of 11 September 2026.

What were Yogi Ltd's latest quarterly results?

Yogi Ltd reported revenue of ₹48.6 Cr and a net loss of ₹1.6 Cr for the Jun 26 quarter. Revenue fell 46.2% and profit fell 125.6% year on year. Earnings per share were ₹−0.37. — as of 11 September 2026.

What is Yogi Ltd's revenue?

Yogi Ltd reported revenue of ₹48.6 Cr in the Jun 26 quarter, −46.2% year on year. For the full FY26 fiscal year, revenue was ₹439 Cr (+295.5%). — as of 11 September 2026.

What is Yogi Ltd's profit?

Yogi Ltd earned ₹−1.6 Cr of net profit in the Jun 26 quarter, −125.6% year on year. Full-year FY26 profit was ₹21.0 Cr. — as of 11 September 2026.

What is Yogi Ltd's market cap?

Yogi Ltd's market capitalisation is ₹707 Cr at a share price of ₹161. Market cap is the share price multiplied by shares outstanding, so it is restated whenever the price moves. — as of 11 September 2026.

What is Yogi Ltd's P/E ratio?

Yogi Ltd trades at a P/E of 54.1×, at the 68th percentile of its own 1-year range, against a long-run median of 40.2×. This is a comparison with the stock's own history, not a value call — as of 11 September 2026.

Does Yogi Ltd pay a dividend?

Yes — Yogi Ltd's dividend payout was 5% of profit in FY26, and it recorded a payout in 1 of its last 3 reported fiscal years. This page holds the payout ratio, not a per-share amount. — as of 11 September 2026.

Is Yogi Ltd overvalued?

On its own history, Yogi Ltd looks expensive: its P/E of 54.1× sits at the 68th percentile of its 1-year range (long-run median 40.2×). That is a percentile read against the stock's own past, not a price opinion or a direction call. — as of 11 September 2026.

Is Yogi Ltd growing?

Not right now — Yogi Ltd's latest numbers are shrinking: latest-quarter revenue −46.2% year on year, profit −125.6%. The earnings engine currently reads: deteriorating — as of 11 September 2026.

How is Yogi Ltd performing?

Yogi Ltd is in a confirmed uptrend, 172 weeks in. Its latest quarter's revenue fell 46.2% and profit fell 125.6% year on year. Against the NIFTY 500 it has been behind on a trailing-13-week view for 2 weeks. This describes what the data did, not a rating. — as of 11 September 2026.

Is Yogi Ltd in an uptrend?

Yes — the price is in a confirmed uptrend (week 172 of stage 2), trading −1.2% versus its 200-day average and at 22% of its 52-week range. Price stages cycle base → advance → top → decline, and the stage names where this stock sits in that cycle — as of 11 September 2026.

Is Yogi Ltd beating the market?

Not lately — on a trailing-13-week view Yogi Ltd is currently behind the NIFTY 500 (2 weeks and counting; last ahead the week of 2026-08-28), the same metric the week-by-week ribbon on this page draws. Separately, on the cumulative view: over the last 10.5 years the stock moved +1,894% against the NIFTY 500's +267% — ahead of the index over the full window. — as of 11 September 2026.

Will Yogi Ltd's share price go up?

This page publishes no price forecast for Yogi Ltd. What it measures instead: the share price is ₹161, the price is in a confirmed uptrend 172 weeks in. Its P/E of 54.1× sits at the 68th percentile of its own 1-year range. — as of 11 September 2026.

Who owns Yogi Ltd?

Promoters hold 62.7% of Yogi Ltd, foreign institutions null%, domestic institutions null% and the public 37.3% (latest quarter). The biggest move on the register over the last two years: Promoters added 8.3 points over 8 quarters. — as of 11 September 2026.

Does Yogi Ltd have too much debt?

It carries real leverage — Yogi Ltd's debt-to-equity is 1.82. FY26 borrowings were ₹253 Cr against equity of ₹139 Cr. Read the returns on this page with that leverage in mind — as of 11 September 2026.

What is Yogi Ltd's capex?

Yogi Ltd spent ₹9.0 Cr on capital expenditure over the last 2 fiscal years, a figure derived from the change in fixed assets plus depreciation. In FY26 alone that was ₹9.0 Cr, with ₹0.0 Cr in capital work-in-progress — capacity paid for but not yet earning. — as of 11 September 2026.

What is Yogi Ltd's cash flow?

Yogi Ltd consumed ₹192 Cr of operating cash in FY26 — cash flowed out rather than in (free cash flow: ₹−201 Cr). Operating cash was negative while the company reported a profit of ₹21.0 Cr. Cash-flow resolution for India is annual. — as of 11 September 2026.

Is Yogi Ltd's profit real cash?

No — operating cash was negative over the last 2 fiscal years: Yogi Ltd consumed cash while reporting profit. In FY26, operating cash was ₹−192 Cr against reported profit of ₹21.0 Cr. Cash-flow resolution is annual — as of 11 September 2026.

What could break the Yogi Ltd story?

The sharpest disagreement: annual EPS moved +1,255.6% against a −9.1% price move — the market has not yet caught up with the delivery. Mechanically, two Friday closes in a row below the 200-day average would end the price trend — that is the exit rule this page tracks — as of 11 September 2026.

Is Yogi Ltd a stock worth studying right now?

This is not investment advice. The machine read: Yogi Ltd's three tracks disagree. Price, valuation and the earnings engine each tell a different story — the next quarter or two settles it. The sharpest open question: whether the price catches up with earnings that have already moved. Every number on this page is drawn deterministically from the raw series, with no forecasts and no price opinions — as of 11 September 2026.

Sector Alpha — machine-written from the numbers · Data as of 2026-09-11. Every chart on this page is drawn by deterministic code from the raw series — no forecasts, no price opinions, and nothing here is investment advice.

Not SEBI Registered !! Not Investment advice !!

Chat with this pageChat with pageChatChatGPTClaudePerplexityGoogle AI